MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • MDS Virtual Congress 2020

    Effects of Sleep Disorders on the Quality of Life in Parkinson’s Disease: A Study of 84 Ibadan Patients

    R. Oguntoye (Ibadan, Nigeria)

    Objective: To assess the effects of sleep disorders on the quality of life in PD patients. Background: Parkinson’s disease is a progressive neurodegenerative disease. The…
  • MDS Virtual Congress 2020

    Urinary Symptoms and Parkinson’s Disease: The Patient’s Perspective

    J. Wertheimer, B. Reynolds, C. Walton, J. McNamara, T. Hamran, S. Freedland (Los Angeles, CA, USA)

    Objective: To learn about prevalence rates and the impact of urinary symptoms on day-to-day function and quality of life from the patient’s perspective. Background: Urinary…
  • MDS Virtual Congress 2020

    Dietary and Plasma Polyunsaturated Fatty Acids in Parkinson’s Disease

    D. Yoo, Y. Lim, T. Ahn (Seoul, Republic of Korea)

    Objective: We assessed the dietary intakes and plasma levels of polyunsaturated fatty acid (PUFA) in Parkinson's disease (PD), and their relation to motor and non-motor…
  • MDS Virtual Congress 2020

    Donepezil for mild cognitive impairment in Parkinson’s disease: A 48-week follow-up study

    K. Baik, S. Kim, S. Kang, Y. Sohn, P. Lee, S. Kang (Seoul, Republic of Korea)

    Objective: To investigate the efficacy of donepezil for mild cognitive impairment (MCI) in Parkinson’s disease (PD). Background: MCI is common in PD. The mechanism of…
  • MDS Virtual Congress 2020

    Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations

    D. Jennings, P. LeWitt, D. Kern, I. Goodman, A. Siderowf, O. Omidvar, A. Ellenbogen, J. Aldred, R. Macuica, S. Huntwork-Rodriguez, C. Ho, M. Troyer (South San Francisco, CA, USA)

    Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…
  • MDS Virtual Congress 2020

    Rapid on-time onset and sustained improvements in motor states throughout the day following treatment with levodopa/carbidopa intestinal gel (LCIG) vs immediate-release levodopa/carbidopa oral capsules (LCIR)

    R. Pahwa, J. Aldred, N. Gupta, E. Terasawa, V. Garcia Horton, D. Macaulay, P. Kandukuri, Y. Jalundhwala, Y. Bao, P. Kukreja, S. Isaacson (Kansas City, KS, USA)

    Objective: To assess the speed of on-time onset and characterize the patterns of motor states throughout the day in advanced Parkinson’s disease patients treated with…
  • MDS Virtual Congress 2020

    A Discrete-Choice Experiment Evaluating Preferences for On-Demand Treatments for Patients with Parkinson’s Disease and “OFF” Episodes

    A. Thach, J. Sutphin, J. Coulter, C. Mansfield (Marlborough, MA, USA)

    Objective: To quantify patient preferences for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD develop potentially disabling “OFF”…
  • MDS Virtual Congress 2020

    Euphoria-inducing lead contacts: mapping of image and electrophysiology in Parkinson’s disease

    Y.C Chen, C.H Yeh, P.H Tu, P.L Chen, H. Wu, M.K Yang, C.C Chen (Taoyuan, Taiwan)

    Objective: We characterized stimulation-induced euphoria during the programming of STN DBS. The lead contacts where euphoria was elicited were characterized anatomically and electrophysiologically. Background: Mood…
  • MDS Virtual Congress 2020

    Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease

    J.C Martinez Castrillo, I. Parees Moreno, G. Sanchez Diez, A. Alonso Cánovas (Madrid, Spain)

    Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…
  • MDS Virtual Congress 2020

    Automated classification of neurodegenerative parkinsonian syndromes using multimodal magnetic resonance imaging in a clinical setting

    L. Chougar, J. Faouzi, N. Pyatigorskaya, O. Colliot, S. Lehéricy (Paris, France)

    Objective: To evaluate the accuracy for the categorization of parkinsonian syndromes of a machine learning algorithm trained with a research cohort and tested on an…
  • « Previous Page
  • 1
  • …
  • 110
  • 111
  • 112
  • 113
  • 114
  • …
  • 388
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #23660 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley